Drug intelligence / Profile preview

GSK1399686

Development stage: Phase 2
Lead developer: GSK
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

GSK1399686 is an orally administered anti-inflammatory macrolide conjugate compound developed by GSK. It was investigated primarily for the treatment of ulcerative colitis and other inflammatory bowel diseases. The drug acts as a small molecule and functions as a 50S ribosomal subunit inhibitor, targeting bacterial protein synthesis pathways. Clinical trials reached up to Phase 2 for ulcerative colitis, but there is no evidence of approval or ongoing development beyond these studies[2][5][6].

Brand names: ASACOL
Other names: 1399686GSK-1399686GSK1399686GSK 1399686

Targets

Bacterial 50S ribosomal subunit

Beyond the preview

Go deeper on GSK1399686.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK1399686.

Explore the full profile